Abstract: The subject invention provides a method of treating an individual afflicted with early stage Dupuytren's disease characterized by the presence of one or more nodules on the individual's hand which comprises injecting into each nodule a pharmaceutical composition comprising an amount of an antihuman TNFa antibody or fragment thereof effective to treat the individual, wherein the pharmaceutical composition is in the form of a liquid and between 0.1 ml and 0.6 ml of the composition is injected into each nodule. This invention also provides for a pre-filled syringe for carrying out the above-described method.

Abstract: The subject invention provides a method of treating an individual afflicted with early stage Dupuytren's disease characterized by the presence of one or more nodules on the individual's hand which comprises injecting into each nodule a pharmaceutical composition comprising an amount of an antihuman TNFa antibody or fragment thereof effective to treat the individual, wherein the pharmaceutical composition is in the form of a liquid and between 0.1 ml and 0.6 ml of the composition is injected into each nodule. This invention also provides for a pre-filled syringe for carrying out the above-described method.

Abstract: This invention provides polypeptides represented by the following formula: H2N-A-X—B-A-X—B—HOOC which are based on HMGB1 as well as compositions comprising, and treatment methods using, such polypeptide.

Abstract: The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The subject invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a TNF receptor 2 (TNFR2) antagonist effective to treat the patient.

Abstract: The subject invention provides a method of treating an individual afflicted with early stage Dupuytren's disease characterized by the presence of one or more nodules on the individual's hand which comprises injecting into each nodule a pharmaceutical composition comprising an amount of an antihuman TNFa antibody or fragment thereof effective to treat the individual, wherein the pharmaceutical composition is in the form of a liquid and between 0.1 ml and 0.6 ml of the composition is injected into each nodule. This invention also provides for a pre-filled syringe for carrying out the above-described method.

Abstract: The present invention provides method, uses and agents for preventing or reducing cognitive decline in a patient following a planned inflammatory trigger. Such planned inflammatory trigger can be a surgical procedure or chemotherapy. The invention further provides methods, uses and agents for reducing cognitive decline in a patient with a cognitive disorder, wherein said patient has been exposed to an inflammatory trigger. Pharmaceutical compositions and kits are also provided.

Abstract: The subject invention provides a method of preventing or treating a condition associated with a defect in, or damage to, an organ in a subject with, or at risk for, such defect or damage to such organ which comprises administering to the subject a therapeutically effective amount of the fully reduced (all thiol) form of HMGB1 or a biologically active truncated form of HMGB1, so as to prevent or treat such condition. The subject invention also provides a method of improving regeneration of blood in a subject comprising administering a therapeutically effective amount of the fully reduced (all thiol) form of HMGB1 or a biologically active truncated form of HMGB1, effective to improve regeneration of blood.

Abstract: The present invention provides method, uses and agents for preventing or reducing cognitive decline in a patient following a planned inflammatory trigger. Such planned inflammatory trigger can be a surgical procedure or chemotherapy. The invention further provides methods, uses and agents for reducing cognitive decline in a patient with a cognitive disorder, wherein said patient has been exposed to an inflammatory trigger. Pharmaceutical compositions and kits are also provided.

Abstract: The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The subject invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a TNF receptor 2 (TNFR2) antagonist effective to treat the patient. The invention additionally provides a method of treating a patient suffering from liver fibrosis of lung fibrosis which comprises administering to the patient an amount of a TNFR2 antagonist effective to treat the patient.

Abstract: The subject invention provides a method of preventing a consequence of an anticipated injury in a subject which comprises administering to the subject a therapeutically effective amount of the fully reduced (all thiol) form of HMGB1 or a biologically active truncated form of HMGB1, so as to prevent the consequence of the anticipated injury.

Abstract: The subject invention provides a method of treating an individual afflicted with early stage Dupuytren's disease characterized by the presence of one or more nodules on the individual's hand which comprises injecting into each nodule a pharmaceutical composition comprising an amount of an antihuman TNFa antibody or fragment thereof effective to treat the individual, wherein the pharmaceutical composition is in the form of a liquid and between 0.1 ml and 0.6 ml of the composition is injected into each nodule. This invention also provides for a pre-filled syringe for carrying out the above-described method.

Abstract: The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The subject invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a TNF receptor 2 (TNFR2) antagonist effective to treat the patient.

Abstract: Musculoskeletal fibroproliferative disorders, such as Dupuytren's disease may be treated by administering locally a TNF-? antagonist. TNF-? antagonists find particular utility in inhibiting the progression of early disease state Dupuytren's disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such as collagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren's disease and, in particular inhibiting recurrence.

Abstract: The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The subject invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a TNF receptor 2 (TNFR2) antagonist effective to treat the patient.

Abstract: Musculoskeletal fibroproliferative disorders, such as Dupuytren's disease may be treated by administering locally a TNF-? antagonist. TNF-? antagonists find particular utility in inhibiting the progression of early disease state Dupuytren's disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such as collagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren's disease and, in particular inhibiting recurrence.

Abstract: The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a bispecific antibody comprising an IL-33 antigen binding domain of which (i) binds to and inhibits activation of, an IL-33 receptor, or (ii) specifically binds to IL-33 and inhibits IL-33 from binding to the IL-33 receptor, and a TNF antigen binding domain of which (i) binds to and inhibits activation of, a TNF receptor, or (ii) specifically binds to TNF and inhibits TNF from binding to the TNF receptor, wherein the bispecific antibody is effective to treat the patient.

Abstract: The subject invention provides a method of treating a patient suffering from a systemic fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The invention also provides a method of treating a patient suffering from a systemic fibrotic condition which comprises administering to the patient an amount of a bispecific antibody comprising an IL-33 antigen binding domain of which (i) binds to and inhibits activation of, an IL-33 receptor, or (ii) specifically binds to IL-33 and inhibits IL-33 from binding to the IL-33 receptor, and a TNF antigen binding domain of which (i) binds to and inhibits activation of, a TNF receptor, or (ii) specifically binds to TNF and inhibits TNF from binding to the TNF receptor, wherein the bispecific antibody is effective to treat the patient.

Abstract: Musculoskeletal fibroproliferative disorders, such as Dupuytren's disease may be treated by administering locally a TNF-? antagonist. TNF-? antagonists find particular utility in inhibiting the progression of early disease state Dupuytren's disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such as collagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren's disease and, in particular inhibiting recurrence.

Abstract: The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The subject invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a TNF receptor 2 (TNFR2) antagonist effective to treat the patient. The invention additionally provides a method of treating a patient suffering from liver fibrosis of lung fibrosis which comprises administering to the patient an amount of a TNFR2 antagonist effective to treat the patient.

Abstract: The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The subject invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a TNF receptor 2 (TNFR2) antagonist effective to treat the patient.